Azacitidine

被引：137

作者：

Issa, JPJ ^{[1
]}

Kantarjian, HM ^{[1
]}

Kirkpatrick, P ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2005年 / 4卷 / 04期

关键词：

D O I：

10.1038/nrd1698

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];

摘要：

Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.

引用

页码：275 / 276

页数：2

共 17 条

[1]

ANZAI H, 1992, CANCER RES, V52, P2180

[2]

DNA methylation patterns and epigenetic memory [J].

Bird, A .

GENES & DEVELOPMENT, 2002, 16 (01) :6-21

[3]

Epigenetic targets in hematopoietic malignancies [J].

Claus, R ;

Lübbert, M .

ONCOGENE, 2003, 22 (42) :6489-6496

[4]

Epigenetics in human disease and prospects for epigenetic therapy [J].

Egger, G ;

Liang, GN ;

Aparicio, A ;

Jones, PA .

NATURE, 2004, 429 (6990) :457-463

[5]

Novel therapies for myelodysplastic syndromes [J].

Faderl, S ;

Kantarjian, HM .

CANCER, 2004, 101 (02) :226-241

[6]

International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[7]

Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation [J].

Herman, JG ;

Baylin, SB .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2042-2054

[8]

Myelodysplastic syndromes [J].

Hofmann, WK ;

Lübbert, M ;

Hoelzer, D ;

Koeffler, HP .

HEMATOLOGY JOURNAL, 2004, 5 (01) :1-8

[9]

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies [J].

Issa, JPJ ;

Garcia-Manero, G ;

Giles, FJ ;

Mannari, R ;

Thomas, D ;

Faderl, S ;

Bayar, E ;

Lyons, J ;

Rosenfeld, CS ;

Cortes, J ;

Kantarjian, HM .

BLOOD, 2004, 103 (05) :1635-1640

[10]

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia [J].

Kantarjian, H ;

Gandhi, V ;

Cortes, J ;

Verstovsek, S ;

Du, M ;

Garcia-Manero, G ;

Giles, F ;

Faderl, S ;

O'Brien, S ;

Jeha, S ;

Davis, J ;

Shaked, Z ;

Craig, A ;

Keating, M ;

Plunkett, W ;

Freireich, EJ .

BLOOD, 2003, 102 (07) :2379-2386

← 1 2 →